Natera (NTRA) Launches Zenith Genomic Assay

On March 12, 2026, Natera, Inc. (NASDAQ:NTRA) announced the commercialized motorboat of Zenith, a whole-genome sequencing assay engineered to importantly amended the diagnosis of uncommon familial conditions. Zenith, with its genomic analysis, aims to shorten the diagnostic odyssey for the 30 cardinal Americans affected by uncommon diseases. In its announcement, the institution pointed retired the immense unmet request successful the assemblage and noted that the cumulative economical load of uncommon diseases successful the U.S. reached astir $997 cardinal successful 2019 alone. Using the caller objective instrumentality volition supply entree to timely and close results that could importantly assistance successful providing definitive answers to families of uncommon illness patients.

In an unrelated event, Morgan Stanley lowered its terms people connected Natera, Inc. (NASDAQ:NTRA) from $265 to $250 connected March 3, 2026, aft updating its exemplary pursuing the fourth-quarter results. The steadfast kept an Overweight standing connected the company’s stock.

Founded successful 2004, Natera, Inc. (NASDAQ:NTRA) is simply a person successful cell-free DNA (cfDNA) investigating for oncology, women’s health, and organ health. Its office is successful Texas.

While we admit the imaginable of NTRA arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Best Stocks to Invest successful During a Recession and 10 Best Space Exploration Stocks to Buy According to Analysts

Disclosure: None. Follow Insider Monkey connected Google News.